Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company that develops and commercializes medicines for kidney disease and related conditions. Its commercial products are Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults on dialysis, and Auryxia (ferric citrate),… From the company’s description.
Over the twelve months to Sep 30, 2026, Akebia Therapeutics, Inc. reported revenue of $197.20M, down 12.4% from a year earlier, and a net loss of $44.56M. Its operating margin was −15.7%, and operations generated $15.78M in cash. In fiscal 2025, it reported revenue of $236.20M, up 47.5% from fiscal 2024, and a net loss of $5.34M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Akebia Therapeutics, Inc. does
In the company’s own words
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company that develops and commercializes medicines for kidney disease and related conditions. Its commercial products are Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults on dialysis, and Auryxia (ferric citrate), an oral medicine for elevated phosphorus in adults on dialysis and iron deficiency anemia in adults with non-dialysis-dependent kidney disease. The company also develops treatments for rare kidney diseases and other indications, including praliciguat for focal segmental glomerulosclerosis, AKB-097 for complement-mediated kidney diseases, and early-stage HIF-based candidates. Akebia markets both commercial products in the United States, while partners market Vafseo and ferric citrate in certain countries abroad. Its portfolio includes the Auryxia, Vafseo and AKEBIA Therapeutics brands. Auryxia joined the portfolio through Akebia’s 2018 merger with Keryx Biopharmaceuticals. For the fiscal year ended December 31, 2025, the company reported $[revenue figure not provided] in revenue. Its website is www.akebia.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1517022
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Akebia Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Akebia Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Akebia Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Akebia Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Akebia Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”